These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30346831)

  • 21. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
    Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
    Castro M; Zangrilli J; Wechsler ME; Bateman ED; Brusselle GG; Bardin P; Murphy K; Maspero JF; O'Brien C; Korn S
    Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
    Li J; Wang F; Lin C; Du J; Xiao B; Du C; Sun J
    J Asthma; 2017 Apr; 54(3):300-307. PubMed ID: 27435534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reslizumab as add-on therapy in patients with refractory asthma.
    Virchow JC; McDonald M; Garin M; Korn S
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma.
    Nair P; Bardin P; Humbert M; Murphy KR; Hickey L; Garin M; Vanlandingham R; Chanez P
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):555-564. PubMed ID: 31626990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials.
    Virchow JC; Katial R; Brusselle GG; Shalit Y; Garin M; McDonald M; Castro M
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):540-548.e1. PubMed ID: 31404668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-IL-5 treatments in severe eosinophilic asthma: real life datas].
    Özdel Öztürk B; Bavbek S
    Tuberk Toraks; 2020 Jul; 68(2):148-159. PubMed ID: 32755115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on reslizumab for eosinophilic asthma.
    Cardet JC; Israel E
    Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.
    Eger K; Kroes JA; Ten Brinke A; Bel EH
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1194-1200. PubMed ID: 33069885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 40. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.